Jones Financial Companies
DMAC icon

Jones Financial Companies’s DiaMedica Therapeutics DMAC Stock Holding History

Jones Financial Companies’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,622
Closed -$63.8K – 4262
2025
Q2 		$63.8K Buy
+16,622
New +$64.8K ﹤0.01% 2133

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Jones Financial Companies's DMAC Position: Q3 2025 in Review

Jones Financial Companies sold out of DiaMedica Therapeutics (DMAC) in Q3 2025, closing a stake of 16,622 shares — an estimated $63.8K sold.

Jones Financial Companies first reported a position in DMAC in Q2 2025 and held it in 1 quarter. The position peaked at $63.8K in Q2 2025. 78 funds tracked by Wall St. Rank hold DMAC as of Q3 2025.

  • Jones Financial Companies reported no remaining DiaMedica Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jones Financial Companies sold 16,622 DiaMedica Therapeutics shares in Q3 2025, an estimated $63.8K.
  • Jones Financial Companies first reported a position in DiaMedica Therapeutics in Q2 2025 and held it in 1 quarter.
  • Jones Financial Companies's DiaMedica Therapeutics position peaked at $63.8K in Q2 2025.
  • 78 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2025.

Based on Jones Financial Companies's 13F filing for Q3 2025, filed 4 Nov 2025.